08:42 AM EDT, 09/11/2025 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Thursday that paxalisib monotherapy completely disrupted large circulating tumor cell clusters in blood samples from stage IV HER2-positive breast cancer patients in an ex vivo study conducted by QIMR Berghofer.

The company said the treatment also showed "statistically significant reduction" in single circulating tumor cells, which are linked to metastasis and aggressive disease.

The findings suggest paxalisib may have potential in HER2-positive disease, where current treatment options remain limited, according to Kazia.

The company said the results build on earlier data showing reductions in tumor cell clusters in triple-negative breast cancer.

Shares of the company were up more than 7% in recent Thursday premarket activity.